 FORT COLLINS, Colo., Aug. 5, 2021 PRNewswire -- Cytocom Inc. NASDAQ: CBLI, a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today provided shareholders with an update regarding its recent merger with Cleveland BioLabs. 